Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-89. (Canceled)

90. (Currently Amended) A method of screening an antibody for activity in inducing clearance of clearing an amyloid deposit of Aβ, comprising:

combining the amyloid deposit, the antibody, and microglial cells bearing Fc receptors in a medium in vitro; and

by a series of measurements, measurements monitoring whether a reduction in the amount of the amyloid deposit remaining in the medium occurs, as compared to a baseline measurement, the reduction a reduction in the amount of the amyloid deposit indicating the antibody [[has]] induces phagocytic clearing activity of the microglial cells against the amyloid deposit.

- 91. (Currently Amended) The method of claim 90, wherein the amount of the amyloid deposit remaining is monitored by monitoring the amount of an antigen associated with the amyloid deposits remaining in the medium, wherein the antigen is $A\beta$ or another antigen associated with the amyloid deposit.
- 92. (Previously Presented) The method of claim 90, wherein the combining comprises combining the amyloid deposit and the antibody before adding the microglial cells bearing Fc receptors.
- 93. (Previously Presented) The method of claim 90, wherein the amyloid deposit is a tissue sample from the brain of an Alzheimer's disease patient or an animal having Alzheimer's pathology.

Application No. 09/724,288 Amendment dated July, 20 2007 Reply to Office Action of April 23, 2007

- 94. (Previously Presented) The method of claim 91, wherein the antigen is Aβ.
 - 95. (Canceled)
- 96. (Previously Presented) The method of claim 90, wherein the monitoring is performed microscopically.
- 97. (Previously Presented) The method of claim 90, wherein the antibody is a monoclonal antibody.
- 98. (Currently Amended) The method of claim 97, wherein the monoclonal antibody binds to an epitope within amino acid residues 1-7 of $A\beta$.
 - 99. (Canceled)
- 100. (Previously Presented) The method of claim 97, wherein the amyloid deposit is a tissue sample from the brain of an Alzheimer's disease patient or an animal having Alzheimer's pathology.